Marit Muri Holmen

923 total citations
19 papers, 491 citations indexed

About

Marit Muri Holmen is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Marit Muri Holmen has authored 19 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Marit Muri Holmen's work include Breast Cancer Treatment Studies (6 papers), Cancer Genomics and Diagnostics (6 papers) and BRCA gene mutations in cancer (5 papers). Marit Muri Holmen is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), Cancer Genomics and Diagnostics (6 papers) and BRCA gene mutations in cancer (5 papers). Marit Muri Holmen collaborates with scholars based in Norway, United States and Canada. Marit Muri Holmen's co-authors include Pål Møller, Anne Irene Hagen, Lovise Mæhle, Anita Vabø, Hildegunn S. Aase, Per Skaane, Bjørn Naume, Jaran Apold, Olav Engebraaten and Kjell Arne Kvistad and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Cancer.

In The Last Decade

Marit Muri Holmen

17 papers receiving 480 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marit Muri Holmen Norway	10	199	187	141	123	114	19	491
Woo-Chul Noh South Korea	8	122 0.6×	173 0.9×	86 0.6×	117 1.0×	140 1.2×	18	383
M. Rudas Austria	9	90 0.5×	177 0.9×	156 1.1×	52 0.4×	169 1.5×	24	412
Zhimin Shao China	12	62 0.3×	187 1.0×	112 0.8×	26 0.2×	94 0.8×	23	362
J. Chakrabarti United Kingdom	6	141 0.7×	137 0.7×	158 1.1×	47 0.4×	39 0.3×	11	410
Teiji Umemura Japan	15	69 0.3×	227 1.2×	194 1.4×	177 1.4×	141 1.2×	37	684
Angela Cramer United Kingdom	10	83 0.4×	176 0.9×	287 2.0×	133 1.1×	93 0.8×	19	506
Yiqiong Zheng China	11	93 0.5×	174 0.9×	112 0.8×	32 0.3×	62 0.5×	26	428
B Gairard France	13	42 0.2×	160 0.9×	337 2.4×	213 1.7×	101 0.9×	32	644
Ruohong Shui China	13	70 0.4×	225 1.2×	158 1.1×	36 0.3×	187 1.6×	32	432
A‐Yong Cao China	12	29 0.1×	260 1.4×	272 1.9×	238 1.9×	174 1.5×	40	606

Countries citing papers authored by Marit Muri Holmen

Since Specialization

Citations

This map shows the geographic impact of Marit Muri Holmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marit Muri Holmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marit Muri Holmen more than expected).

Fields of papers citing papers by Marit Muri Holmen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marit Muri Holmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marit Muri Holmen. The network helps show where Marit Muri Holmen may publish in the future.

Co-authorship network of co-authors of Marit Muri Holmen

This figure shows the co-authorship network connecting the top 25 collaborators of Marit Muri Holmen. A scholar is included among the top collaborators of Marit Muri Holmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marit Muri Holmen. Marit Muri Holmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Holmen, Marit Muri, et al.. (2023). Downgrading of referrals to breast cancer patient pathway. Tidsskrift for Den norske legeforening. 143(7).

Falk, Ragnhild Sørum, et al.. (2021). Patterns of aggressiveness: risk of progression to invasive breast cancer by mammographic features of calcifications in screen-detected ductal carcinoma in situ. Acta Radiologica. 63(5). 586–595. 2 indexed citations

Bergholtz, Helga, Tonje G. Lien, Giske Ursin, et al.. (2019). A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue. Journal of Mammary Gland Biology and Neoplasia. 24(2). 163–175. 3 indexed citations

Höglander, Elen, Silje Nord, David C. Wedge, et al.. (2018). Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations. Genome Medicine. 10(1). 92–92. 18 indexed citations

Dumeaux, Vanessa, Hans E. Fjøsne, Marit Muri Holmen, et al.. (2017). Interactions between the tumor and the blood systemic response of breast cancer patients. PLoS Computational Biology. 13(9). e1005680–e1005680. 19 indexed citations

Evans, D. Gareth, Elaine F. Harkness, Anthony Howell, et al.. (2016). Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hereditary Cancer in Clinical Practice. 14(1). 8–8. 38 indexed citations

Haugen, Mads H., Ole Christian Lingjærde, Marit Krohn, et al.. (2016). Abstract 3268: Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - a randomized phase II study. Cancer Research. 76(14_Supplement). 3268–3268. 3 indexed citations

Engebraaten, Olav, Laxmi Silwal‐Pandit, Marit Krohn, et al.. (2015). Abstract P4-11-14: Molecular response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva - a randomized phase II study. Cancer Research. 75(9_Supplement). P4–11. 2 indexed citations

Engebraaten, Olav, Laxmi Silwal‐Pandit, Silje Nord, et al.. (2015). Molecular characteristics in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva— Randomized phase II study.. Journal of Clinical Oncology. 33(15_suppl). 2523–2523.

10.

Møller, Pål, Astrid Stormorken, Marit Muri Holmen, et al.. (2014). The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation. Breast Cancer Research and Treatment. 144(3). 607–614. 7 indexed citations

11.

Dumeaux, Vanessa, Josie Ursini‐Siegel, Arnar Flatberg, et al.. (2014). Peripheral blood cells inform on the presence of breast cancer: A population‐based case–control study. International Journal of Cancer. 136(3). 656–667. 20 indexed citations

12.

Møller, Pål, Astrid Stormorken, Christoffer Jonsrud, et al.. (2013). Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Research and Treatment. 139(1). 155–161. 38 indexed citations

13.

Haakensen, Vilde Drageset, Ole Christian Lingjærde, Torben Lüders, et al.. (2011). Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Medical Genomics. 4(1). 77–77. 29 indexed citations

14.

Fangberget, Anne, Line Brennhaug Nilsen, Knut Håkon Hole, et al.. (2010). Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. European Radiology. 21(6). 1188–1199. 119 indexed citations

15.

Haakensen, Vilde Drageset, Ole Christian Lingjærde, Marit Muri Holmen, et al.. (2010). Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Research. 12(4). R65–R65. 38 indexed citations

16.

Hagen, Anne Irene, Kjell Arne Kvistad, Lovise Mæhle, et al.. (2007). Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. The Breast. 16(4). 367–374. 135 indexed citations

17.

Helland, Åslaug, Hilde Johnsen, Anna Barbro Sætersdal, et al.. (2006). Radiation-induced effects on gene expression: An in vivo study on breast cancer. Radiotherapy and Oncology. 80(2). 230–235. 17 indexed citations

18.

Fosså, Sophie D., Harald Holte, Marit Muri Holmen, et al.. (2005). [Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma].. PubMed. 125(1). 41–4. 2 indexed citations

19.

Dørum, Anne, et al.. (2004). 029 Ovarian Screening in Hereditary Breast-Ovarian Cancer Families. 10 Years Follow-Up. International Journal of Gynecological Cancer. 14. 9–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact